jhoff - InterAx Biotech

DEC 2019

9. March 202330. December 2019 by jhoff

InterAx Biotech and GPCR Therapeutics Inc collaborate for the identification of compounds with superior biological properties targeting GPCR heteromers using the InterAx systems biology platform

Seoul, South Korea and Villigen, Switzerland – 9th of December 2019
InterAx Biotech AG announced today that it has entered an agreement with GPCR Therapeutics, a biopharmaceutical company focusing on developing drugs targeting disease-specific GPCR heterodimers. “The long-standing in-house expertise on the biology of GPCR heteromers and chemokines at InterAx and the cutting-edge approach of GPCR Therapeutics in targeting relevant heteromers in cancer has resulted in an exciting collaboration. Our unique computational approach to characterize specific signaling patterns of relevant GPCR heteromers will help to identify compounds with superior biological properties”, says Maria Waldhoer, CSO at InterAx. “We are also delighted to be working with an uprising biopharmaceutical company in South Korea, as we are for the first time introducing our platform beyond European borders.”
“We are excited to have the opportunity to partner with InterAx to prioritize drug candidates targeting GPCR heteromers. We hope that combining our innovative platform to target cancer-specific GPCR heteromers with InterAx systems biology modeling will ultimately lead to major discoveries that will benefit patients,” says Dr. Dong Seung Seen, the CEO of GPCR Therapeutics, Inc.

About InterAx
InterAx Biotech AG is pioneering computational pharmacology for drug discovery. The Swiss company is uniquely positioned to assist drug candidate design and selection for G protein-coupled receptors in collaborative projects with Biotech and Pharma companies. InterAx applies mathematical models and simulations to in-house derived bioanalytical data in order to address the complexity of drug-induced cellular signaling mechanisms.
For more information, please visit www.interaxbiotech.com.

About GPCR Therapeutics
GPCR Therapeutics Inc. is a biopharmaceutical company focusing on developing drugs targeting disease-specific GPCR heteromers. The diversity of GPCR heterodimerizations and their modes of action represent an unprecedented challenge and opportunity to discover novel drug targets and develop new drugs with higher specificity and less side effects. By taking novel approaches to targeting GPCR heteromers, the south Korean company is developing innovative pharmaceuticals to address unmet medical needs.
For more information, please visit www.gpcr.co.kr.

Printer friendly version

APR 2019

9. March 202328. April 2019 by jhoff

InterAx Biotech and Lundbeck A/S entered an agreement to enable the in-depth characterization of drug candidates using the proprietary InterAx systems biology platform

Switzerland – Denmark, April 2019 Villigen
InterAx Biotech AG announced today that it has entered an agreement with Lundbeck A/S to enable the in-depth characterization of drug candidates using the proprietary InterAx systems biology platform. InterAx and Lundbeck will combine their expertise in the characterization of drug candidates for an undisclosed target. “We are delighted to assist Lundbeck in their quest to identify compounds with superior biological properties for their target receptor with our unique technology”, says Maria Waldhoer, CSO at InterAx. Financial terms of the partnership were not disclosed.

About Lundbeck
H. Lundbeck A/S (LUN.CO, LUN DC, HLUYY) is a global pharmaceutical company specialized in psychiatric and neurological disorders. For more than 70 years, Lundbeck A/S has been at the forefront of research within neuroscience.

About InterAx
InterAx Biotech AG is pioneering computational pharmacology for drug discovery. The Swiss company is uniquely positioned to assist drug candidate design and selection for G protein-coupled receptors in collaborative projects with Biotech and Pharma companies. InterAx applies mathematical models and simulations to in house-derived bioanalytical data in order to address the complexity of drug-induced cellular signaling mechanisms.

FEB 2019

9. March 202328. February 2019 by jhoff

InterAx Biotech received the Seal of Excellence by the European Commission

February 2019, Switzerland-Belgium : InterAx is proud to announce that we received the Seal of Excellence by the European Commission, as the institution managing Horizon 2020, the EU Framework Programme for Research and Innovation 2014-2020 for its Disruptive GPCR Lead Discovery Platform Delivering New and Safer Therapeutics.

JAN 2019

9. March 202320. January 2019 by jhoff

InterAx Biotech closed a financing round of CHF 3 million

January 2019, Switzerland : InterAx, a Biotech company pioneering computational pharmacology for drug discovery, has closed a financing round of CHF 3 million. The investment round was led by Falcon III Ventures and investiere. The new funds will be used to accelerate commercialization of the technology platform which enables intelligent drug candidate design and selection. InterAx appoints Dr. Bettina Ernst as a new member of the board of directors. She brings in additional extensive and valuable experience from the biotech and pharmaceutical industry.